General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
Revenue vaulted ₹873 crore in FY26, a threefold leap from ₹299 crore the year prior. Yet net profit—₹34 crore—feels thin against that headline. The company has been rewriting its script, swallowing overseas acquisitions and capital raises while the promoter stake crumbled from 58.6% to 5.93% in a single quarter.
That collapse isn’t drama. In December 2024, Anubhav Agarwal (then the main promoter at 55.23%) faded into the woodwork. Global Focus Fund, M7 Global, and a constellation of foreign names now own the majority. The balance sheet holds ₹72 crore invested in Epitome Industries and carries ₹50.65 crore in borrowings.
Operating margin limped to 2.5%—barely breathing. A company that had no revenue two years ago is now a ₹2,744 crore market cap entity holding more cash equivalents than operating profit.
Is this a turnaround or a shell game with better optics?
2 — Introduction
BN Agrochem (formerly Arihant Tournesol and then BN Holdings) was incorporated in 1991. For most of its life it was dormant—losing money, reporting no sales, a dusty ticker. In FY24, it stirred. Revenues appeared: ₹7 crore. Losses shrank. By FY26, something snapped awake: the company reported ₹873 crore in sales.
What changed? Overseas ambition. In FY24–FY25, the company:
- Incorporated wholly-owned subsidiaries in London (BN Holdings Europe) and Singapore (BN Agrochem Singapore).
- Raised external commercial borrowings and issued ₹40 crore in foreign currency convertible bonds.
- Acquired a 3.5% stake in Epitome Industries India via ₹72 crore in preference shares.
- Allotted 17.9 crore convertible warrants to Global Focus Fund for ₹82.49 crore.
By May 2026, Chintan Ajaykumar Shah became CEO; the founder Anubhav Agarwal stepped back to non-executive chair. Auditors changed. A CFO resigned hours before results. The numbers, in short, are a window into a company mid-metamorphosis.
3 — Business Model: WTF Do They Even Do?
The company deals in oilseeds, edible oils, solvent extraction, refined oils, and oil cakes. On paper, it is an agrochem and food FMCG play. In reality, it is an investment holding company that acquired an operating business.
The operating engine lives in two subsidiaries in Europe and Singapore. The holding company receives trade receivables and other financial assets (₹142 crore as of March 2026), sits on ₹72 crore invested in Epitome, and collects small management fees. This is a classic structure for capital deployment and international tax arbitrage.
The business generates revenue not through branded consumer goods but through commodity oil trading. Two customers—Agusta Global DMCC and KLB International—account for 29% and 58% of revenue respectively. That is a concentration risk that barely needs a chart to be alarming. Lose one, lose the majority of the P&L.
4 — Financials Overview
Figures are consolidated, in ₹ crore.
| Metric | FY2026 | FY2025 | YoY Growth |
|---|---|---|---|
| Revenue | 873.28 | 299.41 | 191.5% |
| EBITDA* | 23.45 | 7.81 | 200.1% |
| PAT | 34.37 | 19.76 | 73.9% |
| EPS (annualised) | 3.52 | 2.02 | 74.3% |
*EBITDA = PBT + Interest + Depreciation = 19.77 + 1.94 + 0.77 = 23.45 cr.
Q4 FY26 (Quarter ended 31 Mar 2026): The quarter itself reported ₹261 crore revenue, ₹4.22 crore operating profit, and ₹2.95 crore net profit. That implied annualised Q4 EPS of ₹0.30 (not multiplied, as Q4 is the full year-close). Full-year annualised EPS: ₹3.52.
Operational Commentary: Revenue growth was brisk; profitability did not keep pace. Operating margin (OPM) was 2.53% for the year—the company kept ₹2.53 of every ₹100 of revenue as operating profit. The prior year’s OPM was 2.3%. Gross spread widened. The tax rate was -74%, a substantial reversal (likely deferred tax benefits or past-year adjustments), which inflated reported net profit but does not reflect cash earnings.
5 — Market Expectations & Historical Multiples
This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.
| Metric | Current | Historical Average (3yr) | Peer Median |
|---|---|---|---|
| P/E | 79.8 | 49.9 | 23.9 |
| EV/EBITDA | 117.3 | N/A | 18.4 |
| P/B | 5.88 | N/A | 2.73 |
| ROE | 8.01% | 13.2% | 5.03% |
| ROCE | 4.38% | 27.2% | 5.95% |
The market currently pays 79.8x earnings here versus a peer median of 23.9x. The company’s own 5-year average P/E (trailing) was 49.9x, a figure that captured earlier volatility when earnings were negative or microscopic.
On book value, the market values the company at 5.88x net worth, above the peer median of 2.73x. This suggests investors are pricing in future growth or intangible value (the Epitome stake, the overseas subsidiaries, the capital-raising capacity) that the current operating business does not justify on an accounting basis.
Return on equity (ROE) at 8% is below the peer median of 5.03%, yet it has halved from the 3-year average of 13.2%—a deterioration. Capital employed (equity + debt) generated 4.38% returns (ROCE), well below the cost of capital. This is the market’s way of saying: the balance sheet is loaded with capital that isn’t earning its keep.
6 — What’s Cooking
Promoter Exit & Institutional Ownership (Dec 2024–Mar 2026). Anubhav Agarwal, the founder and majority owner, held 55.23% in December 2024 and 5.93% by March 2026. The shares moved into the hands of Global Focus Fund (18.34%), M7 Global Fund (12.14%), and other offshore entities. This is a material shift in control, not a gradual sale.
CFO Resignation (May 2026). Manisha resigned effective May 31, 2026, hours before audited results were announced. Anurag Bansal took over. In a company this young and this capital-hungry, CFO churn signals unresolved tension over financial direction.
Auditor Change (May 2026). The statutory auditor shifted from a prior firm to JSMG & Associates. Both issued unmodified opinions, but the change is notable on a ₹2,700+ crore market cap entity.
Epitome Stake (₹72 crore). The company holds 3.5% convertible preference shares in Epitome Industries India. Epitome is a related company in edible oil manufacturing. This is a bet on consolidation or a capital-friendly holding until conversion or exit.
External Commercial Borrowing (₹40 crore). In FY24, the company raised USD 40 million (roughly ₹330 crore notional) via foreign currency convertible bonds. These are due in 2027–2028. A conversion would dilute shareholders; redemption would strain cash. This is a ticking obligation.
Leverage Reduction. Borrowings fell from ₹83.11 crore (Mar 2025) to ₹50.65 crore (Mar 2026). The company paid down ₹32.46 crore in net debt. This is a positive signal, but the base is still high relative to operating EBITDA of ₹23.45 crore—a 2.16x debt-to-EBITDA multiple.
Merger of Subsidiaries (Apr 2026). The CCI approved a merger of three group companies on April 28, 2026. BSE issued no-objection on March 4. This is a simplification: three operating entities folding into one listed vehicle.
7 — Balance Sheet
| Item | Mar 2026 | Mar 2025 |
|---|---|---|
| Total Assets | 525.64 | 662.06 |
| Equity (Share Capital + Reserves) | 466.69 | 391.42 |
| Borrowings | 50.65 | 83.11 |
| Other Liabilities | 8.30 | 187.54 |
Assets shrank ₹136 crore year-on-year, mostly because trade receivables fell from ₹289 crore to ₹142 crore (working capital tightened). Equity grew ₹75 crore despite no dividend payout—retained earnings, plus the ₹82.49 crore warrant warrant proceeds less capital deployment.
Three observations:
- The receivables collapse (from ₹289 cr to ₹142 cr) suggests either aggressive collection, a revenue mix shift toward faster-paying customers, or a reduction in trade credit terms—good housekeeping if genuine.
- Equity is now ₹466.69 crore; borrowings are ₹50.65 crore. The D/E ratio improved to 0.11x, a healthy posture for a company this young.
- The balance sheet has nothing to hide—it is transparent in its lack of conventional assets. No plant, minimal inventory, no goodwill. It is pure financial engineering: cash, receivables, and one strategic investment (Epitome).
8 — Cash Flow: Sab Number Game Hai
| Year | Operating | Investing | Financing |
|---|---|---|---|
| FY2026 | 24.04 | 23.51 | -43.30 |
| FY2025 | -31.27 | -290.39 | 328.04 |
| FY2024 | -3.08 | -72.00 | 75.39 |
Operating cash flow turned positive (₹24 crore) in FY26 after two years of outflows. Investing cash flow swung from -₹290 crore (FY25’s ₹72 crore Epitome investment) to +₹23.51 crore (asset sales or receivables recoveries). Financing outflow of ₹43.30 crore was debt repayment.
The pattern is a three-year capital deployment cycle: raise money, invest, operate, harvest. Cash is now flowing from operations. That is the turning point, but the base is small—₹24 crore operating cash against ₹873 crore revenue implies a 2.75% cash conversion. Margins are still being debugged.
9 — Ratios: Sexy or Stressy?
| Ratio | Value | Note |
|---|---|---|
| ROE | 8.01% | Equity is earning low single-digit returns. |
| ROCE | 4.38% | Capital (debt + equity) is generating less than 5% returns. |
| PAT Margin | 3.94% | Bottom line captures ₹3.94 per ₹100 of sales. |
| D/E | 0.11 | Leverage is low. |
| P/E | 79.82 | The stock trades at 80x earnings. |
The math is blunt: a company earning 4.4% on capital, trading at 80x earnings, is pricing in a dramatic margin or ROCE inflection—or it is a speculative bet on the international expansion and the Epitome stake. ROE fell from 13.2% (3-year average) to 8%, a regression toward single digits.
10 — P&L Breakdown: Show Me the Money
| Year | Revenue | EBITDA | PAT |
|---|---|---|---|
| FY2026 | 873.28 | 23.45 | 34.37 |
| FY2025 | 299.41 | 7.81 | 19.76 |
| FY2024 | 7.09 | -2.12 | -3.13 |
The company went from loss-making in FY24 to profit in FY25. By FY26, revenue tripled and PAT doubled—but EBITDA did not: it merely tripled. The gap between EBITDA (₹23.45 cr) and PAT (₹34.37 cr) is a -74% tax rate—deferred tax reversals and past-year adjustments. This is accounting gain, not operational gain.
The real story: revenue is inflating faster than profitability. Margins are tight, cash conversion is slow, and the company is not yet compressing expenses to match its newfound scale.
11 — Peer Comparison
| Company | Revenue (₹ cr) | PAT (₹ cr) | P/E |
|---|---|---|---|
| Redington | 119,162 | 1,594 | 11.58 |
| MSTC | 369.66 | 218.43 | 18.32 |
| BN Agrochem | 873.28 | 34.37 | 79.82 |
| Vintage Coffee | 553.05 | 72.19 | 32.18 |
| Creative Newtech | 2,704.61 | 70.29 | 15.06 |
The peer set is a ragtag mix of trading, investment, and agrochem companies. BN Agrochem is smallest by absolute profit but largest by multiple. It earns at least 20 times fewer rupees than Redington (₹34.37 cr vs ₹1,594 cr PAT) but trades at 7x the P/E (79.8x vs 11.58x). Creative Newtech is a ₹2,700 crore revenue behemoth on a 15x multiple; BN Agrochem is a ₹873 crore upstart on 80x. The market is betting hard on the turnaround.
12 — Miscellaneous: Shareholding & Promoters
| Category | Mar 2026 (%) |
|---|---|
| Promoters | 5.93 |
| Global Focus Fund | 18.34 |
| M7 Global Fund | 12.14 |
| Other Foreign Funds | 30.59 |
| Public | 94.07 |
| FII/DII | 0.00 |
The public now owns 94% of the company. Anubhav Agarwal, the founder, holds 5.93%. The rest is scattered among US and offshore funds. This is a complete ownership flip.
Anubhav Agarwal founded the company and was chairman until May 2025. He built the Epitome relationship and raised the USD 40 million bond. Then he exited, leaving Chintan Shah (a newcomer as of August 2025) as CEO. It is unclear whether this was a planned succession or a forced out. Either way, the founder’s retreat is a signal worth noting.
13 — Corporate Governance: Angels or Devils?
Board Turnover: Chintan Shah appointed CEO and Whole-Time Director in August 2025; Anubhav Agarwal stepped to non-executive chair. In May 2026, Agarwal was re-designated as Chairman. Sandeep Chauhan joined as Independent Director in August 2025.
Auditor Change: Auditor changed in May 2026. Both prior and new auditors issued unmodified (clean) opinions.
Compliance Fines: BSE levied fines of ₹76,700 (May 2026) and ₹1,22,720 (October 2025) for delayed disclosures and non-submission of annual reports. Minor sums, but they flag administrative sloppiness.
Tax Situation: The consolidated tax rate was -74% in FY26 (tax benefit of ₹14.6 crore on PBT of ₹19.77 crore). This is a deferred tax reversal—the company had loss carryforwards from prior years and is now using them to offset tax. It is legal but not recurring. Standalone, the tax rate was worse: the standalone entity reported a net loss of ₹59.65 crore in FY26 (vs consolidated profit of ₹34.37 crore), indicating the bulk of profits came from overseas subsidiaries or the Epitome holding.
Related-Party Transactions: The Epitome stake is a related-company acquisition. The overseas subsidiaries were incorporated to house acquisitions and borrowings. These are not red flags (many holding structures use subsidiaries), but they require scrutiny—especially with a founder exit and an institutional buyer base.
14 — Industry Roast & Macro Context
The edible oil sector in India is commoditized, fragmented, and price-sensitive. Tariffs on imported oils, monsoon cycles, and global vegetable oil prices drive margins. A small player in a crowded field faces constant margin pressure.
The company’s revenue concentrates on two customers (87% of sales). One customer hiccup, and the P&L disintegrates. BN Agrochem is not a brand; it is a trader. Traders have no moat, no pricing power, and no loyalty—only operational efficiency and relationships.
The overseas play (Europe, Singapore, Liberia) is a bet that global consolidation will be kinder to asset-light Indian entities. That is possible, but it is also speculative. Most Indian agrochem and oils players have exited or consolidated with larger groups.
15 — EduInvesting Verdict
| Strengths | Weaknesses |
|---|---|
| Revenue growth from ₹7 cr (FY24) to ₹873 cr (FY26) | Operating margins of 2.5%; thin for scale |
| Debt reduced from ₹83 cr to ₹50.65 cr | ROCE of 4.4%; capital is not earning its cost |
| Operating cash flow turned positive | 87% of sales from two customers |
| Zero dividend; all cash retained for reinvestment | Founder exit; ownership now 94% foreign funds |
| Unmodified audit opinion | Tax benefit of ₹14.6 cr is non-recurring |
| Opportunities | Threats |
|---|---|
| Epitome merger could consolidate edible oil supply | USD 40 cr convertible bonds due 2027–28 |
| Overseas subsidiaries could scale trading margins | Commodity price volatility |
| Capital deployment still in early innings | Auditor change and CFO resignation signal friction |
A balance sheet with nothing to hide, a multiple with everything to prove. The company is real—revenue is real, cash flow has flipped positive—but it is also young, concentrated, and still finding its operating rhythm. The stock trades as if these problems will solve themselves by 2028. That is optimism.